Ipamorelin for Fat Loss

What ipamorelin is

Ipamorelin is a five-amino-acid growth hormone secretagogue developed at Novo Nordisk in the 1990s. It acts on the ghrelin (GHRP) receptor to trigger a pulse of growth hormone (GH). Its appeal is selectivity. The 1998 pig studies that introduced it found no rise in ACTH or cortisol even at over 200 times the dose needed for half its GH effect; GHRP-2 and GHRP-6 raised both.

Human pharmacology data come from one IV dose-escalation study in 48 healthy men (1999). GH peaked about 40 minutes after the infusion began and fell to negligible levels within about 6 hours; the half-life was about 2 hours.

The fat-loss case and what's missing

The argument is indirect: GH promotes lipolysis, the release of stored fat. Lifters often prefer it to GHRP-6 for cutting, reporting less hunger. At FDA's October 2024 advisory meeting, a speaker supporting compounding said clinicians mostly use it for body composition and sleep.

No human trial has measured fat loss with ipamorelin. FDA's review found no evidence of effectiveness for the two uses it examined, and the committee voted 0-12 (one abstention) against 503A compounding. In a 2001 mouse study, twice-daily ipamorelin injections increased relative fat-pad weight, even in GH-deficient mice, and raised food intake in normal mice. Our overview of fat-loss peptides covers options with human data.

Blood sugar and other trade-offs

GH counters insulin, so raising it tends to raise blood glucose. In a 2-year trial of MK-677, another ghrelin-receptor agonist, fasting glucose in 65 healthy older adults rose about 5 mg/dL and insulin sensitivity fell. No one has measured this in healthy ipamorelin users. Its Phase 2 trial in 117 adults after bowel surgery did record more high blood sugar at discharge than placebo, plus more low potassium and insomnia.

That trial gave 0.03 mg/kg IV twice daily for up to 7 days and missed its primary endpoint (median time to a tolerated meal, 25.3 versus 32.6 hours on placebo). Two people in the ipamorelin group died after treatment ended; the paper didn't say whether the deaths were related, and FDA cites them as a safety concern. Development stopped.

How users report using it

These figures come from vendors and users, not trials. Vendor guidance commonly lists 200-300 mcg per subcutaneous injection 2-3 times daily for 8-12 weeks. Many users instead describe one bedtime dose of 100-300 mcg with Mod GRF 1-29 (CJC-1295 without DAC), with no food for about 30 minutes either side. No study has tested these schedules or the pairing; our CJC-1295 fat-loss article covers the partner compound.

Side effects: trials versus users

Users mostly describe it as mild. The most common forum complaints (self-selected, not a study):

• Water retention, usually temporary
• Tingling or numbness in the hands
• Mild headaches early on
• Drowsiness after bedtime doses

The trial record is thin: single IV doses in healthy men and up to a week of IV use after surgery. FDA found no published animal toxicity studies and no subcutaneous safety data, so long-term safety claims rest on user impressions. Reported sleep benefits also sit oddly beside the trial's extra insomnia, though surgical inpatients aren't healthy users. Our long-term health effects article covers GH-axis risks.

Legal and sport status

As of October 2026, ipamorelin isn't approved anywhere, and FDA still lists ipamorelin acetate in Category 2 for 503B outsourcing facilities (added September 2023) over immunogenicity risk and the IV trial deaths. WADA's 2026 Prohibited List names it under S2.2.4, so it's banned at all times for tested athletes (see our sports rules guide).

What we still don't know

• Whether ipamorelin changes body fat in people at any dose
• How daily subcutaneous use affects glucose and insulin sensitivity
• Whether the cortisol selectivity seen in pigs holds at user-reported doses